Asterasys Co., Ltd.
KKRX:4509505,050.00
KRW
-150.00
(-2.88%)
ISIN
KR7450950001
Return %
Stock
S&P 500
1Y
-67.61
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Eun-Taek Suh
- Full Time Employees
- 88
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seoul South Korea
- IPO Date
- Jan 24, 2025
- Website
- asterasys.com
- Similar Companies
- Business
- Asterasys Co., Ltd. is a South Korea-based medical device company specializing in the research, development, and manufacturing of advanced energy-based aesthetic and smart healthcare equipment. Founded in 2015 and headquartered in Seoul, South Korea, the company designs, engineers, and commercializes non-invasive and minimally invasive clinical systems alongside proprietary consumables for dermatologists, plastic surgeons, and medical aesthetic practitioners worldwide. The company's core product portfolio encompasses high-intensity focused ultrasound (HIFU) systems, radiofrequency (RF) devices, and multi-functional skincare platforms; its primary offerings include the Liftera series (including Liftera-A, Liftera-V, and Liftera 2), which incorporates patented Thermal Diffusion Treatment (TDT) technology with dual line- and pen-type applicators for precision facial lifting, skin tightening, and body contouring; the Coolfase system, a high-frequency monopolar radiofrequency platform equipped with Direct Contact Cooling (DCC) technology for non-surgical skin tightening and dermal collagen remodeling; the Futera Dots device, a minimally ablative fractional multi-polar radiofrequency system engineered for skin resurfacing, scar revision, and epidermal texture restoration; the CoolSoniq and Q-facial therapeutic aesthetic platforms; and proprietary multi-depth replacement cartridges, treatment tips, and consumable accessories that generate high-margin recurring revenues across installed clinical bases. Asterasys operates an end-to-end in-house research and manufacturing infrastructure and distributes its medical equipment across more than 60 countries throughout Latin America, the Asia-Pacific region, Europe, the Middle East, and Africa, deriving the majority of its sales from international markets. In recent corporate developments, Asterasys completed its initial public offering (IPO) and listed its common stock on the KOSDAQ market under ticker symbol 450950 in January 2025; commenced the commercial rollout and international market introduction of its Coolfase monopolar RF device and next-generation Liftera 2 system; broadened its global regulatory footprint through product clearances including Brazil ANVISA certifications, Taiwan TFDA approvals, and Australia ARTG registrations; and achieved South Korea's $10 Million Export Tower recognition in late 2024 to support ongoing overseas expansion and direct sales network development.